东非四国药物警戒体系比较评估
该研究评估埃塞俄比亚、肯尼亚、卢旺达和坦桑尼亚四国药物警戒体系的功能与优劣势。通过审查法规文件、访谈药监机构人员,使用东非共同体协调指标和WHO全球基准工具。结果显示体系有法律框架但报告不足,各国能力差异大,需针对性干预。
要点
- 四国药物警戒体系均有法律框架,但利益相关方报告疑似药品相关伤害不足。
- 肯尼亚、埃塞俄比亚和坦桑尼亚大陆每百万居民ICSR数分别为35.0、6.7和4.1。
- 仅肯尼亚和坦桑尼亚有专项预算和电子ICSR报告系统,四国均无法获取药物利用数据。
核心结论
- 四国药物警戒体系有法律框架,但能力和绩效水平不同,需针对性干预加强。
研究设计与样本
- 审查四国药物警戒法规文件,访谈国家药品监管机构药物警戒部门人员,使用东非共同体协调指标和WHO全球基准工具补充指标。
主要发现
- 所有国家均有接收、处理和沟通疑似不良事件报告的标准操作规程,但报告不足。
- 肯尼亚、埃塞俄比亚和坦桑尼亚大陆上一日历年每百万居民ICSR数分别为35.0、6.7和4.1。
- 评估时卢旺达无运行中的药物警戒系统。
- 每个国家提交ICSR的卫生机构比例≤1%。
- 仅肯尼亚和坦桑尼亚有药物警戒专项预算和电子ICSR报告系统。
临床怎么用
- 临床药学智能体应关注东非四国药物警戒数据报告不足的现状,在用药安全监测中加强疑似药品相关伤害的报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The increased access to medicinal products in Africa is not well-matched with the pharmacovigilance capacity to monitor drug safety. The objective of this study was to assess the functionality and identify the strengths and limitations of the national pharmacovigilance systems in Ethiopia, Kenya, Rwanda, and Tanzania, and compare these systems. METHODS: Legal and statutory documents governing the pharmacovigilance systems of each participating country were examined by assessors prior to on-site review. The staff of the pharmacovigilance unit of the National Medicines Regulatory Authorities (NMRAs) were interviewed using the East African Community Harmonized Pharmacovigilance Indicators tool, supplemented with indicators from the World Health Organization (WHO) Global Benchmarking Tool. Responses were recorded, and data were analyzed. RESULTS: The pharmacovigilance systems were supported by law and regulations in line with international standards. Standard operating procedures for receiving, processing, and communicating suspected adverse event reports were in place, but reporting of suspected medicine-related harm from stakeholders was inadequate in all countries. The number of Individual Case Safety Reports (ICSRs) received by NMRAs in Kenya, Ethiopia, and Tanzania (mainland) were 35.0, 6.7, and 4.1 per million inhabitants, respectively, in the last calendar year. At the time of assessment, Rwanda did not have an operational system. Overall, ≤ 1% of the total number of health facilities per country submitted ICSRs. Only Kenya and Tanzania had a designated budget for pharmacovigilance activities and an electronic ICSR reporting system. The national pharmacovigilance systems in all four countries did not have access to data on drug utilization. CONCLUSIONS: The national pharmacovigilance systems in the four East African countries have policy and legal frameworks defined by law and regulation to conduct pharmacovigilance activities. However, the four national pharmacovigilance systems are at different levels of capacity and performance with respect to conducting pharmacovigilance activities. Targeted interventions are needed to strengthen the pharmacovigilance systems to enable evidence-based decision making for patient safety.
引用
- Barry A, Olsson S, Minzi O, et al. Comparative Assessment of the National Pharmacovigilance Systems in East Africa: Ethiopia, Kenya, Rwanda and Tanzania. Drug Saf. 2020. PMID: 31919794. doi:10.1007/s40264-019-00898-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。